Consensus Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
16.17 ^USD	+0.87%		+1.06%	+10.75%

May. 07	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	MT
May. 06	Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Day One Biopharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bbfbd1dd9f71af12.73XzN3k_KizuVhVbFF5lTxnt7Wfh3tcHGeDZJNPh0f0.uhzDY0lublWsNU0KbAgUFWmEsiW1sYFtYdCfCYqts5i6LLdiSnJ-YKomZg~462e4a1834e07a44802f205351a6cade

Analyst Recommendations on Day One Biopharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	May. 07	MT
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing	May. 06	MT
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing	May. 06	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $33 From $30, Keeps Buy Rating	Apr. 24	MT
JPMorgan Raises Price Target on Day One Biopharmaceuticals to $36 From $32, Maintains Overweight Rating	Apr. 22	MT
Piper Sandler Cuts Price Target on Day One Biopharmaceuticals to $40 From $45, Maintains Overweight Rating	Feb. 28	MT
Wedbush Adjusts Day One Biopharmaceuticals' Price Target to $33 From $35, Keeps Outperform Rating	Feb. 27	MT
Goldman Sachs Cuts Price Target on Day One Biopharmaceuticals to $44 From $50, Maintains Buy Rating	Feb. 27	MT
Wedbush Lowers Day One Biopharmaceuticals' Price Target to $35 From $39, Keeps Outperform Rating	Nov. 07	MT
Wedbush Lifts Day One Biopharmaceuticals' PT to $39 From $38 After Tovorafenib Receives Priority Review, Maintains Outperform Rating	23-10-31	MT
Goldman Sachs Lowers Price Target on Day One Biopharmaceuticals to $54 From $63, Maintains Buy Rating	23-08-08	MT
HC Wainwright Raises Price Target on Day One Biopharmaceuticals to $50 From $45, Keeps Buy Rating	23-06-05	MT
Needham Cuts Price Target on Day One Biopharmaceuticals to $40 From $44, Maintains Buy Rating	23-05-08	MT
BofA Securities Downgrades Day One Biopharmaceuticals to Underperform From Buy, Adjusts Price Target to $9 From $34	23-04-25	MT
Needham Adjusts Price Target on Day One Biopharmaceuticals to $44 From $48, Keeps Buy Rating	23-04-05	MT
Capital One Starts Day One Biopharmaceuticals at Overweight With $40 Price Target	23-02-08	MT
Oppenheimer Initiates Coverage on Day One Biopharmaceuticals With Perform Rating	23-02-03	MT
Piper Sandler Adjusts Day One Biopharmaceuticals' Price Target to $45 From $40, Keeps Overweight Rating	23-01-09	MT
HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $45 From $35, Maintains Buy Rating	23-01-09	MT
Goldman Sachs Adjusts Price Target on Day One Biopharmaceuticals to $62 From $45, Maintains Buy Rating	23-01-09	MT
Wedbush Raises Day One Biopharmaceuticals' PT to $38 From $35 After Positive Topline Results From FIREFLY-1 Study, Keeps Outperform Rating	23-01-09	MT
HC Wainwright Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $35 Price Target	22-12-15	MT
Needham Initiates Coverage on Day One Biopharmaceuticals With Buy Rating, $40 Price Target	22-12-14	MT
Goldman Sachs Initiates Day One Biopharmaceuticals With Buy Rating, Sets Price at $45	22-12-05	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.17 USD

Average target price

35.78 USD

Spread / Average Target

+121.26%

High Price Target

49 USD

Spread / Highest target

+203.03%

Low Price Target

11 USD

Spread / Lowest Target

-31.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Day One Biopharmaceuticals, Inc.

HC Wainwright
Needham & Co.
JPMorgan Chase
Piper Sandler
Wedbush
Goldman Sachs
BofA Securities
Capital One Securities
Oppenheimer

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar